Kalaris Therapeutics Inc beat EPS estimates 100% of the time across 3 reported quarters (3 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.50 | $-0.48 | +4.0% | Beat |
| Q12026 FY2026 | $-0.52 | $-0.46 | +11.5% | Beat |
| Q42025 FY2025 | $-0.56 | $-0.44 | +21.4% | Beat |
Back to KLRS overview · KLRS holders · KLRS KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.